Ramon-Krauel Marta, Amat-Bou Montse, Serrano Mercedes, Martinez-Monseny Antonio F, Lerin Carles
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain.
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain.
J Clin Med. 2021 Nov 16;10(22):5328. doi: 10.3390/jcm10225328.
Overwhelming evidence demonstrates an important role of the gut microbiome in the development of a wide range of diseases, including obesity, metabolic disorders, and mental health symptoms. Indeed, interventions targeting the gut microbiome are being actively investigated as a therapeutic strategy to tackle these diseases. Given that obesity and mental health symptoms are both hallmarks of Prader-Willi syndrome, targeting the gut microbiome may be a promising therapeutical strategy. Only a few studies have investigated the gut microbiome in the context of Prader-Willi syndrome and assessed the efficacy of probiotic supplementation as a therapeutic strategy for this disease. Here, we review the knowledge obtained to this date regarding the gut microbiome in individuals with Prader-Willi syndrome. The limited evidence available indicate that probiotic supplementation improves some metabolic and mental health aspects, however further studies are warranted to determine whether targeting the gut microbiome may constitute a safe and efficient strategy to treat individuals with Prader-Willi syndrome.
大量证据表明，肠道微生物群在多种疾病的发生发展中起着重要作用，包括肥胖、代谢紊乱和心理健康症状。事实上，针对肠道微生物群的干预措施正在作为治疗这些疾病的一种策略而被积极研究。鉴于肥胖和心理健康症状都是普拉德-威利综合征的特征，针对肠道微生物群可能是一种有前景的治疗策略。只有少数研究在普拉德-威利综合征的背景下研究了肠道微生物群，并评估了补充益生菌作为该疾病治疗策略的疗效。在此，我们回顾了迄今为止关于普拉德-威利综合征患者肠道微生物群的相关知识。现有有限的证据表明，补充益生菌可改善一些代谢和心理健康方面的状况，然而，还需要进一步研究来确定针对肠道微生物群是否可能构成一种安全有效的治疗普拉德-威利综合征患者的策略。
